Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR132 | Q9UNW8 | 12/20 | 0.65 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | PPARG | P37231 | 1/20 | 0.58 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.57 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.55 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.55 |
| ▸ | CMKLR2 | P46091 | 1/20 | 0.55 |
| ▸ | CMKLR1 | Q99788 | 1/20 | 0.55 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.53 |
| ▸ | YAP1 | P46937 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1122745 | 0.94 | GPR132 (0.66) | GPR132GAARAB9APPARGSMPD1 | |
| SCHEMBL27638091 | 0.94 | GPR132 (0.66) | GPR132GAARAB9APPARGSMPD1 | |
| SCHEMBL27638098 | 0.93 | GPR132 (0.77) | GPR132SMPD1CMKLR2CMKLR1PTPN1 | |
| SCHEMBL1123407 | 0.93 | GPR132 (0.77) | GPR132SMPD1CMKLR2CMKLR1PTPN1 | |
| SCHEMBL1122743 | 0.92 | GPR132 (0.76) | GPR132GAARAB9APPARGSMPD1 | |
| SCHEMBL1122705 | 0.92 | GPR132 (0.76) | GPR132GAARAB9APPARGSMPD1 | |
| SCHEMBL1123685 | 0.91 | RAB9A (0.71) | GPR132GAARAB9APPARGERAP2 | |
| SCHEMBL1122923 | 0.91 | RAB9A (0.71) | GPR132GAARAB9APPARGERAP2 | |
| SCHEMBL27638041 | 0.91 | RAB9A (0.71) | GPR132GAARAB9APPARGERAP2 | |
| SCHEMBL1123687 | 0.91 | RAB9A (0.71) | GPR132GAARAB9APPARGERAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1644321-B1 | NEW BENZAMIDES AS PPATY MODULATORS | S A L V A T LAB SA (ES) | 2011-02-09 | — | — | EP | disclosed |
| US-20060160894-A1 | Benzamides as ppar modulators | LABORATORIOS S.A.L.V.A.T.,S.A. (ES) | 2006-07-20 | — | — | US | disclosed |
| EP-1644321-A2 | NEW BENZAMIDES AS PPATY MODULATORS | LABORATORIOS S.A.L.V.A.T., S.A. (ES) | 2006-04-12 | — | — | EP | disclosed |
| WO-2004110983-A2 | NEW BENZAMIDES AS PPARϒ MODULATORS | LABORATORIOS S.A.L.V.A.T., S.A. (ES) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160894-A1 | Benzamides as ppar modulators | PPARD, PPARA, PPARG | GPR132 122/4885GAA 3048/4885RAB9A 4567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.